Q2-2020 Home Health & Hospice Update
While the home health and hospice M&A landscape remains relatively strong, deal closings have undoubtedly slowed in the first half of 2020. Strategic acquirers have continued to be active but some private equity investors have delayed pursuing new home health platforms until there is further insight on the long-term impact of PDGM, which has been further clouded due to disruption from COVID-19.
Hospice, on the other hand, has seen little disruption and continues to see a high level of demand from both strategic and private equity investors. Evident by Amedisys’ acquisition of AseraCare Hospice, investors have and will continue to pay premium valuation multiples for hospice organizations.
To print and download the full Home Health & Hospice Update report, please click below…